Navigation Links
Bionovo Announces Presentation at the National Cancer Institute
Date:2/4/2009

EMERYVILLE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced that company researchers will be presenting at the National Cancer Institute's Office of Cancer Complementary and Alternative Medicine's (OCCAM) monthly lecture series. The title of the presentation is "Selective Cytotoxic Activity of BZL 101 Towards Cancer Cells and Anti-Tumor Effects in Patients with Advanced Breast Cancer," and will be presented by Dr. Emma Shtivelman, Bionovo's Director of Cancer Research, and Dr. Mary Tagliaferri, Bionovo's President and Chief Medical Officer.

Dr. Emma Shtivelman earned her Ph.D. in molecular biology from the Weizmann Institute of Science, Israel. She was a postdoctoral associate at the G.W. Hooper Research Foundation University of California, San Francisco. She is the recipient of several awards including J. F. Kennedy Prize of Excellence and the Israeli Parliament Award for Excellence in Studies. Dr. Shtivelman has patents resulting from her work.

Dr. Mary Tagliaferri, a graduate from Cornell University, received her medical degree from the University of California, San Francisco. She also holds a master's degree in Traditional Chinese Medicine from the American College of Traditional Chinese Medicine.

Dr. Tagliaferri has over 13 years experience in translational research with the University of California, San Francisco and Bionovo, Inc. Dr. Tagliaferri has spearheaded multiple scientific R & D projects to develop pharmaceutical agents for indications in women's health and cancer. As one of the co-founders of Bionovo Inc, she has extensive experience with FDA regulatory affairs, and she has successfully filed a number of Investigational New Drug Licenses (INDs). She has been involved in all aspects of drug development, from preclinical testing to developing FDA approved protocols for clinical trials. As the chief medical officer of Bionovo, she currently manages and directs the daily activities of all clinical research projects being conducted at prestigious medical centers throughout the United States and abroad.

The lecture is scheduled to take place on Wednesday, February 4, 2009 from 3:00-4:00 PM EST at Executive Plaza North, 6130 Executive Blvd, Conference Room H, Bethesda, MD 20892. The lecture is open to the public and a webcast will become available a few weeks after the date of the lecture at: http://www.cancer.gov/cam/news/monthly-lecture-series-2009.html

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The Company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and BZL101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bionovo Announces Cost Control Measures Taken
2. Willa A. Hsueh, M.D., Joins Bionovos Scientific Advisory Board
3. Bionovo to Present Recent Findings of BN108, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
4. Bionovo to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
5. John D. Baxter, M.D. Joins Bionovos Board of Directors
6. Bionovo to Present at the Cambria Capital Investor Meeting
7. Bionovo Announces 2007 Financial Results and Highlights
8. Bionovo Describes a New Class of Therapeutic Compounds
9. Bionovo Announces Closing of Public Offering of Common Stock
10. Kensey Nash Announces Director Resignation
11. USP announces new standards to protect patients from counterfeit and adulterated medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... a $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral ... special health care needs in rural and underserved areas. , The Predoctoral Pediatric ...
(Date:7/20/2017)... ... 19, 2017 , ... A July 7th article ... varicose veins in some patients, according to medical experts. Washington State medical clinic ... excessive sitting or standing, or regularly nicking yourself while shaving your legs, and ...
(Date:7/18/2017)... ... 18, 2017 , ... CannaKids, a California Cooperative Cooperation that specializes in the ... the WORLDZ Summit, taking place in Hollywood from July 31-August 1, the Company’s ... cannabis for both pediatric and adult patients, and how the path has led her ...
(Date:7/18/2017)... ... July 18, 2017 , ... The results of an international clinical trial, led in part by ... severe type of muscular dystrophy holds promise for a subgroup of patients. , In a ... and colleagues at 53 study sites in 18 countries describe the clinical benefit of using ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Seattle, Wash., has developed ... to clean, scrub and moisturize the back and other hard-to-reach areas of the body. ... movement in my upper body, particularly my shoulders. I found it difficult to reach ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Corp., also known as ,The Epigenetics Company, announced today the release of ... using the myDNAge ™ test. Based on Horvath,s Clock, so named ... biostatistics at the David Geffen School of Medicine at UCLA ... ™ technology is used to analyze DNA methylation patterns of over ... Epigenetic ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... TRIANGLE PARK, N.C. , July 10, 2017 /PRNewswire/ ... a $5m Convertible Note to support the development of ... by Tencent Holdings Limited, a leading Chinese Internet services ... This funding will advance multiple infectious disease product programs ... Founded by Dr. ...
Breaking Medicine Technology: